Clinical Trial Update: Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) [Phase 2, Phase 3]

View source ↗

Summary

An open-label long-term safety and tolerability study of mavoglurant (AFQ056) in adolescents with Fragile X Syndrome was terminated, with results posted in 2015…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Fragile X Syndrome | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2015-10-12